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Abstract 
Bio-neuronal led psychiatric abnormalities transpired by the loss of neuronal structure and function 
(neurodegeneration), pro-inflammatory cytokines, microglial dysfunction, altered neurotransmission, 
toxicants, serotonin deficiency, kynurenine pathway, and excessively produced neurotoxic substances. 
These uncontrolled happenings in the etiology of psychiatric disorders initiate further changes in 
neurotransmitter metabolism, pathologic microglial, cell activation, and impaired neuroplasticity. 
Inflammatory cytokines, the outcome of dysfunctional mitochondria, dysregulation of the immune 
system, and under stress functions of the brain are leading biochemical factors for depression and anxiety. 
Nanoscale drug delivery platforms, inexpensive diagnostics using nanomaterials, nano-scale imaging 
technologies, and ligand-conjugated nanocrystals used for elucidating the molecular mechanisms and 
foremost cellular communications liable for such disorders are highly capable features to study for 
efficient diagnosis and therapy of the mental illness. These theranostic tools made up of multifunctional 
nanomaterials have the potential for effective and accurate diagnosis, imaging of psychiatric disorders, and 
are at the forefront of leading technologies in nanotheranostics openings field as they can collectively and 
efficiently target the stimulated territories of the cerebellum (cells and tissues) through molecular-scale 
interactions with higher bioavailability, and bio-accessibility. Specifically, the nanoplatforms based 
neurological changes are playing a significant role in the diagnosis of psychiatric disorders and portraying 
the routes of functional restoration of mental disorders by newer imaging tools at nano-level in all 
directions. Because of these nanotherapeutic platforms, the molecules of nanomedicine can penetrate 
the Blood-Brain Barrier with an increased half-life of drug molecules. The discoveries in nanotheranostics 
and nanotherapeutics inbuilt unique multi-functionalities are providing the best multiplicities of novel 
nanotherapeutic potentialities with no toxicity concerns at the level of nano range. 
Key words: Psychiatric disorders, nanotheranostics, nanotherapeutics, neurodegeneration, pro-inflammatory 
cytokines, microglial dysfunction, and kynurenine pathway 
Introduction 
Psychiatric disorders (neurodegenerative 
diseases) occur after a series of intriguing incidences 
such as inflammatory dysfunctions and increased 
neuroinflammation (peripheral and central nervous 
system) [1]. These factors collectively activate 
microglia cells (immune and structural cells) to induce 
the release of pro-inflammatory cytokines interleukin 
(IL) -1β, (IL) -18, and tumor necrosis factor-alpha 
(TNF) -α, that initiates neuronal damages and trigger 
neuron death [2]. These cells further released 
fragmented and dysfunctional mitochondria into the 
brain tissue milieu. Activated microglial cells catalyze 
astrocyte activity and push them to release glutamate 








toxic activity of the central nervous system (CNS), and 
further influence dopaminergic, serotonergic, and 
glutamatergic signaling pathways [3]. Nano-scale 
imaging technologies and ligand-conjugated 
nanocrystals can diagnose molecular mechanisms that 
govern the cellular communication of mental illness. 
It makes the diagnosis by sensing the surface of 
phase-sensitive neuronal as part of a cerebellum 
tissue, and also further, the neurotransmitter diffusion 
in the brain assist the imaging of multifaceted neural 
activities quantitatively and qualitatively under the 
electrical and chemical stimulations. In absence of 
proper diagnostics tools, and improper scientific 
knowledge, mental illnesses (depression, anxiety 
disorders, addictions, personality disorders, 
schizophrenia, eating disorders and addictive 
behaviors) remain undiagnosed, and because of it, 
patients cannot address such diseases at the time of 
initiation that leads to devastating consequences 
(individual suffering, shattered relationships, and 
health complications) which may emerge any time [4]. 
Therefore, nanotheranostics and nanotherapeutics are 
the best tools available to treat psychiatric disorders 
(depression, hopelessness, mood disorders, anxiety 
disorders, schizophrenia, post-traumatic stress 
disorder, addictive behaviors, eating disorders, and 
personality disorders). These include: developing 
nanodevices for (the diagnosis of the disease), 
nanocarriers (better drug delivery), and nanorobots 
(to commensurate nanotherapeutics as per the 
demand of neurophysiological correlations with 
depression and other mental illnesses) [5]. 
The attitudes and behaviors concerning one's 
illness are products of deduced practices to 
commemorate, and therefore, it can be affected by 
cognitive dysfunctions. To understand the mental 
states of other, it is necessary to replay upon "to see 
ourselves as others see us". This improves the abilities 
to know the mental statuses (opinions, beliefs, 
awareness, and intentions) of others. Therefore, the 
correct outlook to moody alteration in oneself 
depends on the abilities to reveal upon personality as 
a prospective, and that is, the priority of the theory of 
mind. Insight has to think of as a relational concept 
that serves as the light of understanding into 
something i.e. understanding illness, pathological 
nature traits, specific symptoms, current syndrome, 
and social difficulties, etc. [6]. Therefore, the 
nanomedicine with inbuilt and self-protected abilities 
to prevent themselves from degradation during 
surface modification into distinct molecules during 
the action, so it can be used for the sophisticated 
detection of signals from the mental state, neural, 
physiological, and muscle. Neurology, psychology, 
and psychiatry mechanisms are the key components 
that take part in the various functions of the 
physiology and are highly responsible for disorders of 
the brain. Elementary motors and sensory processes 
are the key features of adequate assessment of “brain 
function” that govern cognition and behavior [7]. 
These symptoms are (1) interlinked by psychological 
processes, (2) investigated by psychological upset, (3) 
initiated secondary psychological reaction, and (4) 
psychological manifestations that (5) affect the brain. 
Finally, there are many pieces of evidence for 
elucidating the role of neuroinflammation in various 
psychiatric illnesses as abnormal neurotransmission, 
serotonin deficiency, because of the changes in 
neurotransmitter metabolism, pathologic microglial 
cell activation, impaired neuroplasticity, and 
structural and functional brain changes responsible 
for cognition and emotional behavior [9]. Psychoses 
clinically expressed as cognitive conditions, 
(delusions, delirium, dementia, schizophrenia, and 
hallucinations) of the brain. Inflammatory cytokines 
and increased production of neurotoxic substances for 
postulating the link and culprit among the key causes 
for enhancing disease progression [10]. As per an 
emerging theory, the main devil is stress, which plays 
a key role in initiating the deregulation of the immune 
system in psychiatric diseases, alongside genetic, 
epigenetic, and environmental factors. Illnesses such 
as schizophrenia, autism, depression, and other mood 
disorders linked with inflammation of the brain, 
however, the exact underlying mechanisms of these 
kinds of relationships are specific to each illness. The 
outcome of any dysregulation of the immune system 
in the brain might lead to the origin and occurrence of 
depression and anxiety. The analysis of the imbalance 
in the cytokines’ concentration, the inflammatory 
component, verify the psychiatric symptoms and 
inflammation [11], which can initiate stress and 
anxiety to activate depression. To encounter such 
negative effect and paraphernalia of these factors on 
the physiology of the nerve cells, there is a need to 
develop such well-equipped nanocarriers with 
specific abilities and multifunctional capabilities 
(transport for hydrophobic entities, active and passive 
targeting, size exclusion, potential to detect diseases 
(as imaging tools), deliver treatments without toxicity 
[12]. They can easily circulate through blood vessels, 
uniformly distributed, penetrate the cell membranes, 
with the ability to hold macromolecules and not let 
decompose it outside and inside the cell. These 
nanoplatforms derived from multifunctional 
nanomaterials of specific properties can serve as 
diagnostic tools, monitoring sites, for the treatment 
and prevention of diseases (inflammatory conditions, 
neurodegenerative and psychiatric diseases, diabetes, 
and infectious diseases) [13,14]. The negative effects of 




the dysregulated cytokine networks may start the 
pathogenesis of affective disorders (depression and 
anxiety). Therefore, further investigation of the causes 
responsible for inflammation in psychiatry disorders, 
and how these correlate themselves with the known 
alterations in the mechanism of each disease, may 
further create new opportunities for the development 
of a more satisfactory treatment/intervention, method 
and it will have particular effectiveness to prevent 
diseases. In our impression, it is an attempt to develop 
new strategies towards the proper understanding of 
the applications of nanomaterials in cognitive 
behavior/cognitive sciences [15]. 
Insights of molecular mechanisms 
underlying Psychiatric Disorders 
Toxicants enter cellular, molecular, and 
inflammatory pathways to start the initiation of 
processes for the origin of diseases. These foreign 
objects damage the brain's cellular process. These 
destructions in the functioning of neurotransmission 
processes and protein networking cycles propagate 
the pathogenesis of neuropsychiatric diseases. To 
encounter these undesirable difficulties in the cell's 
physiology, the cytokines, an interface regulator for 
interactions and communications between cells, 
stimulate the neuronal defense fortresses of immune 
cells to secrete anti-inflammatory cytokines for 
healing the prolonged pain [16]. A variety of specific 
cytokines and their neutralizing antibodies 
recommended for clinical use may be a potent remedy 
to cure stroke, Alzheimer’s disease, amyotrophic 
lateral sclerosis, autoimmune diseases, and wound 
healing. Some organs cannot stop the entry of 
toxicants in the absence of a compact Blood-Brain 
Barrier (BBB) and thus enhance the probability of 
neurodegeneration [17]. The excessive extracellular 
cerebral excretion process of glutamatergic cytokine 
interferes in excitotoxicity induced by it in 
neuropathology. The other side of defense systems, 
microglia are there as the key component during such 
reaction mechanisms of the neuron, the activation of 
these components of neurons during neuro-
inflammation, initiate the release of mediators (nitric 
oxide, chemokines, and proinflammatory cytokines). 
It is crystal clear that the reactive oxygen species/ 
reactive nitrogen species (ROS/RNS), free radical 
nitric oxide (NO∙), and its derivative the peroxynitrite 
(ONOO-), an influential oxidant, capable to damage 
the biological molecules are among the main 
damaging constituents that exist in brain functioning. 
As in the necrosis process, tumor necrosis factor-alpha 
(TNF) -α medicate cross-linkages between neurons 
and astrocytes for further engagements [18]. 
a) Impact of oxidative stress on the neuron: Lake of 
sufficient oxygen (O2) in the cell causes reduced 
production of ATP. Such dysfunctions force neurons 
to reduce their activities, and as a result, the 
neurodegenerative processes get started. But the 
interrelated mechanism is not still clear and how it 
happened, also not yet discovered. The free radicals 
and non-radical derivatives are there for signal 
sensitization in the brain to deal with oxidative stress 
whenever redox signaling goes awry (negative 
functionality). The ribonucleic acid (RNA) oxidation 
is an underappreciated cause of oxidative stress [19]. 
Undiscovered facts, machinery, and mechanisms 
going on in the neurons are among the main causes to 
dictate neuronal susceptibility, the dynamics of 
oxidative stress, and particularly based on neural 
identity, Figure 1. To disclose the further distinct 
biochemical proceedings, the nanotheranostics must 
urgently employ for the observations of oxidative 
stress in the brain and disease [20]. 
Tight homeostatic control over the production of 
ROS in normal cells, containing neurons, is essential 
for smooth cell regulation. There is a need to detoxify 
ROS, and biological antioxidants (glutathione, 
α-tocopherol (a vitamin E), carotenoids, and ascorbic 
acid), because these react with most of the oxidants 
available at the spot. Besides, the antioxidant enzymes 
(catalase and glutathione peroxidase) detoxify 
hydrogen peroxides (H2O2) by converting it to (O2) 
and water (H2O). Oxidative stress, the deleterious 
condition, occurs whenever ROS intensities go 
beyond the antioxidant volume of a cell. As the 
neurons take part chemically via neurotransmitters 
for chemical transmission, and neuromodulation 
(glutamate, gamma-aminobutyric acid, acetylcholine, 
and peptide transmitters) [21]. An imbalance between 
over-production and/or under-detoxification of 
oxidative/nitrosative stress) leads to hypoxia and 
hypoglycemia, which are the principal causes among 
those who are responsible for oxidative stress [22,23]. 
A lot of modifications in the structural units of lipids, 
nucleic acids, proteins, and modulating the function 
of macromolecules exist in cellular transformation. 
After the initiation of oxidative stress, which leads it 
into either dysfunction or these molecules loose their 
specified activities. As a result, a lot of molecular and 
cellular mechanisms and their interrelated factors 
de-regularize soon. These pathological states initiate 
the degeneration process within the dopaminergic 
neurons. The high intrinsic oxidative stress, low 
adenosine triphosphate assembly, dysregulation, 
dysfunction, and damages of the mitochondrial, and 
extraordinary inflammatory reactions influenced the 
repair the damages and deficient deoxyribonucleic 
acid, propagate low calcium-buffering ability, over 
activation of glutamate receptors, influence the lipid 




turnover, influence protein refolding, DNA base 
excision, and repair [24]. The ROS attack nucleic acids 
in several ways, initiate the breaking in the strand of 
DNA-protein cross-links and may change purine, 
pyrimidine bases resulting in DNA mutations. During 
these cellular processes, the neurons looked for high 
energy, and therefore, there is a high demand for ATP 
production and the same has already reduced because 
of dysfunction of the mitochondrion, and finally, this 
causes a negative impact on neuron functionality [25]. 
Uncontrolled generation of the ROS do damages to 
the cellular components, environment, and organelles 
and initiate apoptosis, and narcosis [26,27]. Neuronal 
networking promotes self-defense through lymphatic 
tissue and glial cells, and starting of the circulation of 
the spinal fluid and white blood cells in the vessels 
during the removal of metabolic waste yields isolated 
toxins, and dead cells. 
b) Inflammasomes in neuroinflammation and 
neurodegenerative diseases: Aggregated host proteins 
(amyloid-β, α-synuclein, and prions), deposits 
abnormally within the cell, and near the territories of 
the cells that initiate neuroinflammation and 
neurodegeneration [28]. Such transformations at 
molecular and cellular levels initiate the 
inflammasomes which start acting as an intracellular 
sensor between microbial (host) and foreign 
pathogens (unwanted guests) by starting signaling for 
unwanted happenings followed by the discharge of 
the inflammatory cytokines interleukin (IL)-1β and 
(IL)-18, in self-defense. In the meantime, other cellular 
processes like pyroptosis ensued to catalyze the 
anti-inflammatory chemicals [1]. The mechanisms of 
inflammasome activation in the brain, controlled by 
 
 
Figure 1. Insights of molecular mechanisms underlying psychiatric disorders. Related steps of Inflammation activation by underling the key roles of endothelial, misfolded 
proteins, neuromuscular junction, inflammatory activation, endothelial cells, T-cells, and dysfunction of neuromuscular. Defected neuron cells: degenerated microglia, 
degenerated astrocytes, inactive macrophages, and Bergmann glia, and degenerated neurons. (A) Brain, brain injury, BBB, neuromuscular junction, misfolded proteins, and 
endothelial cells. (B) Degenerated neurons, microglia, astrocytes, bergmann gila, and inactive macrophages. 




immune cells (microglia). Further, astrocytes, 
neurons, and myeloid cells collectively activate 
inflammasomes to enhance self-defense. This 
discussion highlights the remedial options available 
to treat neuroinflammation and neurodegenerative 
diseases by using nanomedicine induced 
inflammasome as autoimmunity nanotherapeutics 




Figure 2. Neuroinflammation and neurodegenerative diseases by using nanomedicine induced inflammasome as autoimmunity nanotherapeutics. Transformations at molecular 
and cellular levels start the inflammasomes which start acting as an intracellular sensor between microbial (host) and foreign pathogens (unwanted guests) by starting signaling for 
unwanted happenings followed by the discharging the inflammatory cytokines interleukin (IL)-1β and (IL)-18, in self-defense. Adapted with permission from [www.cellsignal.com] 








The cytotoxic consequences and existence of 
aggregated misfolded proteins are liable for chronic 
neuroinflammation and psychiatric disorders [30] 
Errors in protein folding, initiate negativity to disturb 
the normal routines, and the functionalization 
processes of the cells and cellular processes [31]. 
Microglia has a natural ability to sense the existence of 
such irregular happenings within proteins and 
transformation proceedings and promote selected cell 
mechanisms to encounter them and throw 
toxins/harmful substances out of it. Such 
self-cleaning abilities composed of the biochemical 
processes help in regulating neuroinflammation and 
as a result, the stages of neurodegenerative disease 
vanished [32] Thus, the harmful stimuli, 
phagocytizing debris, and apoptotic neurons are 
easily detectable by astrocytes and microglia [18]. 
Soon, nanotheranostics may have such kinds of 
abilities as inbuilt or a much more advanced version 
of it could innovate soon. These newer strategies will 
be available and highly capable of immuno-
modulatory functioning for monitoring synaptic 
homeostasis and facilitating clearance of apoptotic 
cells as ended by astrocytes and microglia [33]. 
Therefore, the need for nanotherapeutics induced 
inflammasomes is the state-of-the-art approaches to 
lead the discovery of better drug formulation for 
novel treatment of neuroinflammation and 
neurodegenerative diseases [34]. 
c) Cellular and molecular neuroinflammatory 
pathways and kynurenine pathway induce 
neurodegeneration: The mechanism of 
neuroinflammation governed by neurovascular units 
(microglial, and glial cells, neuron cells, and 
endothelial cells) perform as a platform to coordinate 
with pro- and anti-inflammatory mechanisms [35]. 
The brain and peripheral cells have to check the 
opening mechanism of inflammatory as interceded by 
cytokines, chemokines, and reactive oxygen species. 
Further, these can easily initiate local or CNS 
inflammation [36]. 
The mechanism of neurovascular unit 
dysfunction affected by neuroinflammation and 
mishappenings as infections. So, the process of 
neuroinflammation is likely to be a normalization 
effort in response to any offense affecting the 
host-defense mechanism [3]. The activation of 
microglia, T-lymphocyte infiltration, and 
overproduction of inflammatory cytokines are the 
first line of offense associated with the restoration of 
normal structural and functional mechanisms of the 
brain [37]. The neutralization process of an infection 
initiated by the discharge of molecular mediators such 
as inflammatory cytokines, and prostaglandin E2, 
caused by nitric oxide, reactive oxygen, and nitrogen 
species and at once act to foil neurodegeneration [38]. 
Thus, cellular and molecular mediators most likely 
assist in pathological processes responsible for a 
disease progression. This has practically proved by 
injecting proteinaceous infectious particles, followed 
by the detection of the symptoms of mental illnesses. 
But a total number of 1,000 trillion viruses and over 
100,000,000,000,000 bacteria have detected in the 
human gut or as per ration 150 times more bacterial 
DNA than human DNA in a human body [39]. 
Viruses (herpes, cytomegalovirus, and HIV) 
normally existed in the brains of diseased persons as 
having the protozoa Toxoplasma gondii. It bases the 
pathways of these mechanisms on different activation 
signals and mediators. These activation signals 
activate cellular phenotypes (astrocytes, microglia, 
and peripheral immune cells), and these signaling 
mechanisms further initiate controlling of the 
cytokines secretion, misfolded protein mechanism, 
and infection [40], and presented in Figure 3. The 
mechanisms of the activation of the phenotypes for 
responding towards the signals received from the 
multifaceted neuron-microglial of the CNS, and how 
they secrete different responding factors to alter the 
signal of forces, are the key mechanisms to highlight 
[41]. What does it happen between the cellular 
phenotypes and the inflammatory mediators? and 
what will the alteration events of the molecular and 
cellular routes, neuronal signals, and receptors 
mechanism? The mechanisms are holding the front. 
By disinterring, such nameless mechanisms of cellular 
activities may further assist in the discovery of novel 
and potential nanotheranostics and related strategies. 
Major transformation and cellular mechanisms, such 
as the association of molecular mechanisms with 
underlying mechanism dysfunction neurovascular 
unit procedure, are among the key pinpoints to learn 
[42]. When all these mechanisms take place on the 
active sites are still unclear. How oxidative injury 
occurred induced by an oxidative burst in microglia, 
amplified by mitochondrial damage and iron 
liberation within lesions, are the impending 
challenges and upcoming soon-to-be [43]. 
d) Mitochondrial dysfunction, reactive astrocytes, 
and neuronal cell death: Concerning dynamics of 
mitochondria governs a lot of important mechanisms 
i.e. ROS production and sequestrations, ATP 
production, intermediate metabolism, 
neurotransmitter generation and degradations, 
apoptosis, and Ca2+ buffering [44]. The mitochondria, 
itself, also undergoes several processes or phenomena 
i.e. mitochondrial fission, fusion, mitochondrial 
bioenergetics, and transport [24]. Other key features 
of these cellular and molecular types of machinery are 
special neurons, astrocytes in the brain governed 




many functions of CNS i.e. glutamate, calcium, 
potassium ions (Ca2+, K+), tissue repair via 
angiogenesis and neurogenesis, energy storage, 
mitochondria biogenesis, defense against 
oxidative/nitrosative stress, and synaptic modulation 
[45]. The disease-specific proteins (aggregated, 
β-amyloid, and α-synuclein), cleared by astrocytes 
through the large-conductance Ca2+-activated K+ 
channels [46]. Upgraded nanotheranostics strategies 
will have to escort with these high profiling cellular 
processes governed by the astrocytes. Such 
innovations will play an important role in the 
innovation of a complete set of nanotherapeutics [47]. 
Here, the most important process or mechanism 
occurs to fulfill the energy needs of the astrocytes. It 
gets completed and fulfilled by mitochondrial 
networking. Any perturbations in the astrocyte and 
mitochondrion energy supply chain reaction, 
immediately distressed neuron functioning and as a 
result, neuronal damage transpired 
(neurodegeneration), Figure 4. The chief causes 
associated with neurodegeneration are dysregulation 
of Ca2+ homeostasis and mitochondrial dysfunction 
[48]. As proof of the pieces of evidence, as 
mitochondrion helped in cytosolic Ca2+ waves and 
global Ca2+ signaling and soon, thereafter, the 
mechanism of dysfunction of mitochondria 
dysregulated Ca2+ related mechanisms responsible for 
the necrotic neuronal death occurred just because of 
dysfunctional and dysregulation [49]. Nano-
theranostics may further explore such hidden and 
undiscovered aspects of these multifaceted 
mechanisms (electron transport mechanism and 
interrelated pathways, decreased ATP production at 
cellular level, decreased pH in the cellular 
environment, increased Ca2+ concentration in the 
cells, the discharge mechanism of glutamate, 
increased concentration of the arachidonic acid, gene 
alterations and activation leading to cytokine 
synthesis, synthesis of enzymes involved in free 




Figure 3. Pathological processes leading to disease progression and the role of phenotypes in neuroinflammation. The oxidative injury occurred induced by an oxidative burst 
in microglia, amplified by mitochondrial damage. The activation signal mechanism activates cellular phenotypes (astrocytes, microglia, and peripheral immune cells), and these 
signaling mechanisms for initiating agents against cytokines, misfolded protein, infectious agents. (A) H. pylori activities on the surface of gastric epithelium, apoptosis cycle (B) 
Components of apoptosis, ribosome (translating), macrophage, TNF, and necrosis. 





Figure 4. The mechanisms of mitochondrial dysfunction, reactive astrocytes, and neuronal cell death. The mechanism of dysfunction of mitochondria dysregulated responsible 
for the necrotic neuronal death. The processes of mental illness cause an assessment of the factors that involve in determining progressions of reported mild dysfunction roots 
psychiatric disorders. (A) Cycle of the injury to the blood vessels (B) Components of the mitochondria, (C) Sodium ion influx, muscle contraction depolarization, (D) Route 
of the action of the mitochondria. 
 
Identifying these critical functional and 
structural changes and their mechanisms of action 
responsible for cell death are still unknown. Shortly, 
only the nanotheranostics will be the best option for 
exploring newer diagnostic and imaging techniques 
to fulfill the existing needs [52]. As, L-tryptophan 
(Trp), known as a watchdog of protein homeostasis, if 
it degrades, then it yields various active molecules of 
metabolites, necessary for metabolism and it classifies 
this pathway as kynurenine pathway. The same 
metabolites influenced cellular components and 
environment (the endocrine, hemopoietic, immune 
system, metabolism pathways, and neuronal 
networking), and ensued kynurenine pathway, a 
necessity for vital cellular functioning and routes [53]. 
The multifactorial nature of the processes of mental 
illness causes an assessment of the factors that involve 
in determining progressions of reported mild 
dysfunction roots of psychiatric disorders [54]. The 
developing strategies (nanotheranostics and 
nanotherapeutics) arrest, heal, and revert these 
progressions responsible for neuron death. 
Nanotheranostics induced molecular 
imaging, diagnosis neuropsychiatry: 
Exploring the mechanisms underlying 
inflammation, and neurodegeneration 
To distinguish between mental illnesses, 
diseases, disorders, or syndromes are the toughest 
task. There is no scientific process available to 
differentiate psychiatric illnesses. In the current 
scenario, no lab test exists in laboratory manuals. The 
documentation of neurobiological features, 
neurotransmitter pathways, structural abnormalities 
on neuroimaging, and genetic predispositions may be 
helpful in this concern [55]. Such references may 
clarify prescriptions, treatment. Features of 
mechanisms underlying psychiatric comorbidities 




(mental illness, neuropsychiatric disorders, chronic 
inflammation, [56], alcohol abuse, personality 
disorders, anxiety, stress, neuropsychiatry disorders, 
eating disorders, neurodegeneration, and Axis II 
features), are the key components of any psychiatric 
diagnoses [57]. Molecular imaging covers an 
unlimited span of research areas and touches the 
inside of the following fields i.e. molecular biology, 
bioengineering, nanotechnology, protein engineering, 
bioinformatics, genomics, transcriptomics, 
metabolomics, and proteomics [58]. Thus, it can 
explore the ins and outs of therapeutics and 
theranostics (diagnose diseases, approach drug 
design, and assess therapies). Molecular imaging 
visualized the complicated biochemical 
transformation of the physiology and pathology of 
disease by targeting the molecular, biochemical 
reactions that represent the mechanism of the 
diseases. The expansion of nanotechnology is further 
shaping the edges of these imaging techniques [59]. 
This is because of nanomaterials assembling with 
molecular imaging that further explores new frontiers 
with developmental abilities of the detection of 
biochemical compositions. Thus, the complexity of the 
new nanotechnologies is making things simpler to get 
better imaging and diagnosis [60]. To diagnose the 
inflammation and neurodegeneration, the 
theranostics platforms must have to overcome the 
blood-brain barrier that is not workable because of the 
complex nature of these natural barriers, Figure 5. 
Thus, there is an urgent need to frame such strategies 
that must have a critical size and ability to remain 
stable during the cross over mechanisms. The 
innovation of nanotheranostics resolved this issue 
[61]. These novel technical inventions are a wide 
range of nanoplatforms, nanocarriers, and 
nanodelivery agents i.e. nanocarriers, nanotube, 
nano-robots, miniatures, nanowires, nanospheres, 
nanoemulsions, and nanogels, [62–65], crystals, 
liposomes, micro-emulsions, solid lipid NPs, and 




Figure 5. The neurobiological features, neurotransmitter pathways, structural abnormalities on neuroimaging, and genetic predispositions. Anorexia regulated possibilities of 
exploring the mechanisms underlying inflammation and neurodegeneration. Possibilities of detection by bioinformatics and modern genomic tools. 




Implementing the novel concept of 
nanotechnology in neuroscience by using newly 
designed nanotheranostics and nanotherapeutics are 
the recent trends and new avenues for treating 
neurological and mental disorders. Some of them can 
act all together as nanotheranostics and 
nanotherapeutics, and such abilities very well 
appreciated and implemented in diagnosis and 
therapy [67]. These strategies gained a lot of scientific 
interest and must implement for the diagnosis of 
neuropsychiatry. Authors are underlining the needs 
and proposing more scientific look on the unique 
properties of the nanocarrier as theranostic and 
therapeutic agents and their application in 
neuropsychiatry, neurological disorders, cognitive 
processing disorders, mental disorders and illnesses 
(dementia, brain injury, psychiatric manifestations, 
epilepsy, movements disorders, cerebrovascular 
accidents, degenerative disorders, and concerned 
domain of neuropsychiatry [68]. A lot of efforts have 
made for the innovation of novel nanodiagnostics and 
nanotherapeutics to treat neuroglial alignment, but, 
still, there is a need to address the current challenges 
and to cover future perspectives for the innovation of 
novel nanotools and nanodevices for the diagnosis 
and treatment of the neurological ailments. 
Nanotheranostics used for molecular diagnosis, 
analysis, and measuring the biological routes in cells 
and tissues to explore pharmacogenomics, and 
pharmacoproteomic information and strategies with 
nanomolar sensitivity by considering environmental 
factors that responded towards therapy [69,70]. 
Nanotheranostics offer advantages of high 
volume/surface ratio and multi-functionality by 
preventing unwanted side-effects. The imaging 
techniques (positron emission tomography [71–73], 
and single-photon emission computerized 
tomography, biomarkers labeled by γ-emitting 
radioisotopes), showed potential empowering the 
localization of the specific drug molecule at the 
targeted sites, cells, and tissues, and therefore at the 
nanoscale, have clinical applications in 
neuropsychiatric disorders [74]. The hormone peptide 
traced is efficient at the nanoscale because of their 
higher binding affinities, easily direct 
neurotransmitter, and very helpful in the regulation 
and monitoring of various disorders (modulation of 
behavior, fierceness, stress, tension, anxiety, alcohol 
intake, and anorexia) [75]. 
Utilization of peptides in neuropharmaceuticals 
and nanotheranostics for diagnosis and cure of a wide 
variety of mental illness, disorders, and 
neuropsychiatry. Designed strategies of 
nanotheranostics based on peptides are recent 
developments for the innovations of tools that 
provide a lot of opportunities for enhancing further 
understanding to diagnose neuropsychiatric 
disorders. The tools of neuroimaging and 
electrophysiology detect the etiology and pathologies 
of CNS disorders and such efforts enhance the 
possibilities of exploring the mechanisms underlying 
inflammation and neurodegeneration [76]. These 
novel modalities highly appreciated for intervening in 
newer theranostic conclusions. It is in demand to 
increase the understanding of the uncovered and 
untouched pathology of CNS disorders. The 
improved version of these technological findings for 
proper diagnosis and imaging are nanotheranostics 
tools. A combined effort of bioinformatics and 
up-to-date genomic methodologies will decisive in 
the innovation of these innovative modalities. Surface 
plasmon resonance approaches to include 
nanoparticles for the detection of Aβ and, to a lesser 
extent, of α-synuclein [77]. Nanoplatforms induced 
gold and silver nanoparticles designed for biomedical 
applications, especially for the innovation of new 
strategies for molecular diagnosis with higher 
analytical capability, sensitivity with the possibility to 
use for neuropsychiatry [78]. These nanodiagnostics 
tools possess very good optical and spectral 
properties i.e. intense localized surface plasmon 
resonance helps in surface modification. Such 
on-demand capabilities of diagnostics tools lead 
towards a comfortable approach to generate natural 
adaptabilities to work with biomolecules. These new 
platforms are proficient in definite molecular 
recognition. These efficient strategies to test molecular 
discovery restricted to nucleic acid (DNA, RNA) and 
protein-based assays. Recently, nano-based devices 
innovated for the diagnosis of mental illnesses [79]. 
There are wearable electronic devices having 
electrodes for detecting electrical muscle signals or 
neuronal signals. These comprise metal and gel 
layers. With a top grade of biocompatibility, no 
resistance with great potential for very good 
detection. 
Nanotherapeutics for Neuropsychiatry: 
Healing insights 
Neurological disorders, yet to diagnose fully, 
need original treatment strategies that remain in 
concern to heal mental illnesses. The major worries 
and successes always remain there in the conscious 
mind because sometimes drug deliveries fail, (unable 
to reach the site) and diagnosis (molecular imaging 
available) succeeds or vice versa because of existing 
multifaceted complications. Therefore, such an 
unclear phenomenon and an incomplete set of tools 
always push earlier diagnosis on the back foot. 
Therefore, the therapeutic option never comes out on 




both fronts [80]. This is the chief cause of the failure of 
treatment. Again, it is acceptable that life-threatening 
coercions always remain lifelong. It is necessary to 
remind again about the major hurdle, the BBB because 
it is the chief cause for unsuccessful diagnosis and 
treatment. Thus, in the absence of a novel method, 
and the drugs used for the treatment methodologies 
underway unwanted neuroimmune activities, this is 
just happening because of unavailability of drugs or 
not fully formed nanoplatforms or integrated drug 
delivery used or unscientific strategies engaged in 
these multifaceted contests. It will use if these 
remedies for healing inside, then such steps could be 
fatal and may cause irreversible damages to neurons. 
The researchers have innovated recently 
nanoplatforms with a plan towards effective drug 
delivery strategies to treat CNS disorders creating no 
perturbation to the brain [81]. Nanocarriers 
(liposomes, nanobubbles, polymeric nanoparticle, 
nanosomes, dendrimers, polymeric micelles, viral 
capsids) designed through computational modeling 
may do wonders by overcoming much-discussed 
huddle i.e. BBB [82]. Drug degradation is also a major 
concern in these drug delivery systems. For targeting 
deeper sites, it must be a stable and highly designed 
drug molecule. So, these drug carriers must 
encapsulate. The delivery of nanocarriers to the CNS 
also hinder by the central nervous system (CNS) and 
BBB extracellular and intracellular barriers [83]. To 
fulfill the need and the demand of such advanced 
delivery carriers with inbuilt abilities (high drug 
filling capability, targeted stroke, reduced 
nanotoxicity, and greater than before therapeutic 
effects), there is an urgent need to develop strategies 
and transform them into reality. Available preferred 
remedies are quite nearer to these proposed 
nanocarriers include different nanotherapeutics and 
nanotheranostics Figure 6. The upcoming challenges 
are there for the search for promising nanocarriers to 
heel neurological and psychiatric disorders, and their 




Figure 6. Nanotherapeutics for neuropsychiatry: Nanotherapeutics enabled with nanoemulsions, nanosuspensions, microemulsions, liposomes, nanobubbles, polymeric 
nanoparticle, or nanosomes dendrimers, solid-lipid nanoparticles, and polymeric micelles, showed promise for neuropsychiatric illnesses (depression, anxiety, and schizophrenia). 
The serotonin-related genetic variants to regulate stress-induced cortisol to activate the neural circuits direct mental illness. (A) Concerned pathways of the brain (B) 
Components of nanotools and nanodevices (C) Selective serotonin mechanism. 




So, there is another concern that arose just 
because of alterations (in cellular processes, drug 
stability, cell organelles preferences), along with 
existing befell in pharmacokinetics and 
pharmacodynamics of the known therapeutics, 
mainly directly linked to the route of administration 
[85], and cellular transformations [86]. Last, future 
perspectives and keenness for the discovering of 
nanotheranostics and nanotherapeutics as CNS/BBB 
drug delivery tools and devices will a major area of 
research in this field. There is a paucity of efficacious 
new compounds to treat neuropsychiatric disorders, 
such as antipsychotic drugs have some side effects 
(involuntary muscle movement, dystonia, metabolic 
disorders, and tardive dyskinesia). Receptor- 
mediated, transported medicated, or adoptive 
mediated transcytosis could be the mechanism 
through which a drug transported across the cell 
membrane by binding proteins or attached with the 
ligands for further pharmacological action [87]. These 
ligands-drug binding formulations have implemented 
in treatment by transporting the drugs beyond BBB. 
The dominant ideology comes from the study of the 
drug target signaling network responses at the 
single-cell level and how the lymphocyte responds 
towards a drug. Therefore, the neuropsychiatric drug 
discovery method always considered such 
multifaceted mechanisms. During the procedure of 
such link establishment, the major happening here is 
primarily T-lymphocytes, which showed functional 
responses on all the sides of neuropsychiatric 
medications to establish targets by an emerging drug. 
These developed therapeutic targets come into 
existence during the phospholipase Cγ1-calcium 
signaling pathway to settle the progress of 
antipsychotic treatment of schizophrenia patients [88]. 
Novel drugs like L-type calcium channel blockers and 
corticosteroids identified as the best therapy available 
and prefer to use during compound library screening. 
These scientific routes further exposed the consistent 
activities of neuronal cells as their responses. For 
speeding up the drug discoveries, there is an urgent 
need to enrich the forecast of the in-vivo effectiveness 
of the targeted drugs prescribed for neuropsychiatric 
condemnations [89]. 
Current therapeutics have a lack of qualities 
(great hepatic metabolism impact, and little half-lime) 
preferred as inbuilt properties to be present in perfect 
therapeutics prescribed for the neuropsychiatric 
illnesses (depression, anxiety, and schizophrenia). The 
efforts for the innovation of novel nanotherapeutics 
held up in the absence of perfect strategies. 
Nanomaterial induced nanocarriers and 
multifunctional nanoplatforms used in their 
designing might be successful and to consider as a key 
component in the innovation of nanoformulation with 
high treatment efficiencies [90]. Such efforts will 
dilute all the challenges that existed in the middle of 
the path of discovery of these novel drug remedies for 
replacing psychotropic drugs. Nanotherapeutics 
enabled with nanoemulsions, nanosuspensions, 
microemulsions, liposomes, nanobubbles, polymeric 
nanoparticle, or nanosomes dendrimers, solid-lipid 
nanoparticles, and polymeric micelles showed 
tremendous promises and proof of this method 
evidenced in-vitro and in-vivo. Such advances are the 
key and the fostering steps in the cycle of discoveries 
required for potential clinical outcomes and benefits. 
These new drug therapies well equipped to treat 
neuropsychiatry and bipolar-like behaviors [91]. To 
identify the gene responsible for and allied with these 
disorders, are a major concern, but these newly 
discovered tiny machines have the potential to 
recognize them with the ability to diagnose and 
identify the concentrations linked with these genes. 
The mechanisms happening in nanodomain existed 
between the area of communication and brain cells. 
These proteins sequencing signaling irregularities 
commonly define as synapses. The mechanism of a 
synapse regulated by gene formulation in the 
nanodomain constituents. Bipolar disorders and 
psychiatric illnesses cause uneven shifts in mood, 
activity, energy level, and day-to-day tasks [92]. The 
stress and environmental factors directly influence the 
correct compositions of the genetic materials and 
degenerate it. However, there is an urgent need to 
specify psychiatric risk and gene degradation. 
Illumination and resolution techniques are the key 
sources for this kind of analysis. The domain area too 
discovered has a very fine architecture that falls to a 
very low range of nanoscale. The abnormalities of 
such bipolar disorders, neuropsychiatry illnesses, and 
leading risk genes interconnect phenomena. 
Therefore, the aim of nanotherapeutics to target these 
genes related issues and a novel procedure needed for 
healing insight are upcoming challenges. 
The monitoring of the drug release, vivo 
imaging, toxicity, current challenges and 
opportunities for future research 
strategies: Nanotherapy for Psychiatric 
Disorders 
Nanomedicines, in nano-therapy, comprise 
nanomaterials, nano biosensors, and nanoscale 
biomaterials to perform as a vehicle and a tool to 
deliver and release the drugs at a precise specific 
target. The therapeutics to treat psychological 
disorders and mental illness [93] have not yet been 
successful because of the complications that existed in 




early diagnosis, frame long disease courses, and in 
addressing the challenges of drug delivery in crossing 
the biological barriers (blood-brain barrier) [84]. 
Recently, nanotherapeutic emerged as a potential tool 
for precise diagnosis, efficient prescription, accurate 
imaging, and distinct psychiatric diseases. 
Hereabouts, this section comprises the advantages 
and disadvantages of nano therapy subsisted in 
psychiatric treatment and the underlying mechanisms 
of disease pathogenesis also outlined [94]. It 
evidenced [95] that the accomplishment of 
nanodevices [95] and nanotools [96] in nanotherapy is 
an excellent approach for correct diagnosis and 
efficient therapy [97]. Consequently, the 
nanomaterials possess an exceptional potential and 
proficiency for molecular/nano-scale interactions, 
therefore at the nanoscale, it must incorporate with 
theranostics and therapeutics for the diagnosis and 
repair of degraded neurons, cells, and tissues [98]. 
Multifunctional nanomaterials included in 
nanomedicines magnify drug release, enhance the 
bioavailability, improve specific target delivery at the 
diseased locality, reliable surface functionalization, 
and capable to penetrate the BBB. Therefore, these 
nanotools and devices will at the forefront of 
diagnostic and therapeutic available as a possible best 
remedy for psychiatric diseases. Mental disorders are 
expanding day by day, but there is no further 
development in novel psychiatric medications. The 
discovery of nanotheranostics and nanotherapeutics 
is addressing the expectations and concerns outlined 
in the treatment of mental disorders [93]. The 
paradigmatic crises addressed well by 
nanotechnology invented novel strategies to innovate 
specific therapeutic [99] to treat neurological [100] and 
psychiatric diseases [101]. In the previous section, the 
authors conclude that nanotherapeutics are the best 
drugs and their carrier’s healing psychiatry. 
Nanotherapeutic and nanotheranostic have infinite 
potential that is worthwhile and essential for 
enhancing therapeutic efficiency, and there is no 
toxicity. Subsequently, based on the sizes (1 and 100 
nm) and shapes of the multifunctional nanomaterials, 
they consider the best resource to feature in drug 
delivery vehicles and prescribed as antipsychotics and 
antidepressant drugs [102]. The variations of (size and 
shapes) exist in the nanotools and nanodevices, which 
execute and induce proficient features to cross the 
biological obstacles (blood-brain barrier). Remedies of 
nanotherapy derived from multifunctional 
nanoparticles perform as antipsychotic and 
anti-depressive agents to treat psychiatric diseases 
and disorders (schizophrenia, depression, and bipolar 
disorder) [103]. Therefore, the nanotherapeutics and 
nanodiagnostics at the nanoscale have variation in 
design, and space in surface atoms and molecules, 
which transform them as the best theranostic and 
therapeutic. 
The authors also critique the trends in 
psychiatric neuroprotection and address future trends 
and challenges by covering the aspects to theoretical 
frameworks based on psychiatric neuropathology and 
its applicability [104]. The neuroprotective factors in 
psychiatry would be exceptionally pertinent to find 
novel treatments and expansion strategies. The 
nanoelectrodes or wearable sensors made of metal 
and outfitted with a gel layer capable of monitoring 
operations, identifying electrical muscle signals 
(electromyography), or neuronal signals 
(electroencephalography), and measure electrical 
conductivity by direct contact with the skin. These 
electrodes, wearable sensors, have biocompatibility, 
low communication permanence, and immense 
capability to adjust with the outline of the skin and 
hence able to detect the signal-to-noise-ratio [105]. The 
detected biological signals used to identify the mental 
states, like neural, physiological, and muscle signals 
and portraiture of mental processes; therefore it has 
considerably enhanced psychic dysfunction analysis 
and operative repair. Shortly, nanotechnology will 
lead as a diagnostic (or neuroimaging) tool for 
assessing brain activity to identify psychiatric and 
neurological disorders. Further, nanotools will 
abolish depression and simultaneously intensify the 
intrinsic neurocognitive [106] potential by the 
atonement of multiple medications, boosting 
bioavailability, retention, and metabolization. 
Silica-based nanocarriers can deliver piracetam, a 
popular racetam nootropic, across the blood-brain 
barrier as a medicine. These nanodevices elaborate on 
the features of psychiatric drugs by enhancing their 
bioavailability to elicit an effect. The strategies of 
nanotherapy designed to treat psychiatric disorders 
also commit to boosting the absorption and as a result, 
it reduces side effects [107]. For example, 
nanotechnology increases the efficacy of 
antidepressants, and then it offers a superior remedy 
that increases the potency of smaller doses. Therefore, 
the pharmaceutical enlarges nanopharmaceuticals 
engendering to treat mental illnesses. 
Nanotechnology ensures drugs optimally as it 
metabolizes and processed by the body. Such a drug 
delivery system illustrates minimal effective dose to 
the target area to minimize side effects. Nanorobots 
may contribute to generating scientific data 
concerning how does neurophysiology strengthens 
during therapy and help for more accurate diagnoses. 
Nanosensors test the efficacy of certain drugs and able 
to provide feedback on the drug’s efficacy, potency, 
and effects [108]. Nanosensors contribute in-depth 




concerning the antidepressant mechanism and 
psychotropic pathways offer entire patient-specific 
data. One of the original help benefits of nanosensors 
is that it allows for universal adoption quickly, safely, 
and effectively. It is possible to implant nanowires, a 
device only 200 nanometers in diameter, within the 
brain to read individualized signals of a patient 
suffering from depression. These nanowires, thin and 
flexible, will help to know how the researcher 
develops recent treatment and would not interrupt 
active neurons. These devices can collect data on 
neurotransmission [109] and nerve signals within the 
brain. 
Nanobots will restore damaged tissue and 
neurons in the brain and are capable to excite definite 
sections of the brain artificially to neutralize 
depression and anxiety. Inserted probes or derived 
from nanomaterials to implant in neurons incite the 
happiest sites inside the brain to balance depressive 
signs. The intensifying brain illness could efficiently 
improve by the pre-programmed nanobots included 
into brains to restore openness, and employed in the 
development of artificial nano-replacements, promote 
stem-cells, renewal of faded cells and tissues [110]. 
Unavoidably, there are noble concerns with the 
nano-neurological enrichment and will plead. 
Nano-scaled implants intentionally change the neural 
pathways in the brain to mimic receptor proteins and 
neural pathways. We reviewed it that certain implants 
proficient to intensify the release of neurotransmitters 
found in excitatory and inhibitory exercise. The initial 
implementation of nanotechnology in psychiatry 
assures to enhance the pharmacokinetic profile and 
effectiveness in various medications. Nanotools 
(liposomes, nanobubbles, nanoparticle polymers, or 
nanosomes) are capable to cross the blood-brain 
barrier with enhanced dose efficiency and dispense 
the drugs at specific neurons in the brain [111]. The 
nanoshells and dendrimers have intensified potency, 
thus capable to gain more enhanced therapeutic 
effects. Specific rigidity and shapes of nanodevices 
and nanotools decide the interaction phenomenon 
between the drug molecules and cell membranes. 
Liposomes are highly capable of the ligand coupling. 
Nanosomes derived from supercritical fluid 
technology is the developed version of liposomes. The 
tiny carriers (nanotubes and polymeric nanoparticles) 
are efficient as a drug carrier to deliver drug 
molecules at a specific target within the brain by 
overcoming the blood-brain barrier and maximize 
drug discharge [112]. It also identifies Nanobubbles as 
tiny bubbles capable of carrying gas molecules within 
a cavity immersed in a liquid solution to enhance the 
effectiveness of pharmaceutical drugs. 
The tiny tools employed to seek space in the 
interworking of neural networks in the dense brain. 
Why is nanotechnology considered treating 
psychiatric illnesses [113], because, it (i) is highly 
capable to resolve the difficulties in 
neuropharmacology by overcoming the blood-brain 
barrier, (ii) can supply drugs at specifically targeted 
cells selectively and accurately (iii) has multiple 
classes of tiny tools (liposomes, nanosomes, 
nanoparticle polymers, nanobubbles) as drug delivery 
agent and always ready to perform various 
responsibility, (iv) can enhance drug bioavailability, 
and pharmacokinetics, (iv) can promote the 
effectiveness of psychotropic drugs with zero 
nanotoxicity, (v) especially, nanoshells and 
dendrimers can live analysis, and (vi) can yield 
specialized compensation in vivo imaging, 
metabolome analysis, and modeling of the central 
nervous system? It is clear from the reported literature 
that new nanoparticles assemblies able to create 
free-scale networking that will perform as artificial 
neural systems for the healing, repair, and functioning 
of synapses, diffusion of a neurotransmitter, and 
mimic synaptic behavior [114]. Nanotools and 
nanodevices are proficient to create nanoparticle 
assemblies, recently termed as artificial intelligence, to 
treat mental illnesses and disorders. Every aspect of 
the nanotechnology look promising, but the safety 
issue is still not addressed fully. It intensified this as 
an ominous state of this technology. These innovative 
strategies used for the diagnosis and treatment of 
neuroinflammation, nerve injury, failure of neuronal 
networking, psychiatric conditions, and brain 
dysfunction [115]. These achievements already show 
the perspicacity into the potential of this 
nanotechnology. 
Dysfunction of Neuronal Networks in 
brain function 
What is the role of neuronal networks in brain 
functioning, how is it responsible for CNS disorders, 
and how is any therapeutics to apply if any 
dysfunction occurred? The most critical aspect is how 
the brain performs many of its major complicated 
tasks. We can only explain this via the investigation of 
neuronal network control [116] and network 
interactions [117]. There is an enormous network that 
experiences important operative changes, resulting in 
substantially original brain functions. The abnormal 
interactions interrupt proper brain functioning, and 
the needed therapeutic to regularize dysfunction by 
network approach is the key feature of this review. 
Thus, the major aspects of neuroscience, 
pharmacology, and psychiatry (neurobiological 
disorders) covered to explore the control mechanisms, 




normal network function, strategies to improve 
therapies for brain disorders [118]. The astrocytes, 
already illustrated in Figure 1, a glial cell, are useful 
portions of the synapses, reacting to neuronal activity 
and coordinating synaptic transmission and 
flexibility. Consequently, neuron-glia networks 
supervise processing, transference, storage, and 
communications of the information by the nervous 
system between astrocytes and neurons reside at the 
cellular and molecular levels but not yet fully 
discovered. It’s evidence that astrocytes are integral 
components of nervous system networks, interlinked 
with intracellular signaling in neuron-glia networks 
[119], and to know it the patterns of structural 
connections in the brain which hold matchless feats of 
perception and a wide variety of behaviors [120]. It is 
possible to do the mapping of these patterns by 
non-invasive imaging techniques. It is an urgent need 
to understand the interior of neurons structure, 
neuron networking, physiology, and functioning style 
and how it care cognitive processes, such efforts will 
crucial for the designing and development of 
simulation-based therapies for mental illness and 
psychiatric disease. 
The communication between complicated 
architecture (neurons and brain regions) concerns 
energy minimization, and information transfer [121]. 
The materialization of wide-range exchanges and 
synchronization from the combined firing of specific 
neurons implore impressions of emergence and 
criticality from mathematical mechanics. By using the 
theories of network control, the designing strategies 
for the innovation of nanotheranostic to cure 
cognitive disorders can accomplish in nanotherapy. 
Therefore, the need to highlight and outline the 
effectiveness of nanotechnology-enabled procedures 
and techniques [122] (electrophysiology and 
intracellular sampling) to understand the brain and its 
components are there [123]. Implementing 
nanotheranostics techniques to interrupt the brain, 
explore breakthroughs to get single-cell resolution, for 
better diagnosis, and monitoring of neurological 
diseases. Nanotools [124] have the potential to 
transport therapeutic and imaging contrast agents 
into the neurons and nerve cells by overcoming the 
blood-brain barrier, clear from the cited literature 
[125]. Nanotools and nanodevices can increase 
drug-drug interactions, facilitate pathogen clearance, 
and promote the transportation of biologically active 
molecules to achieve better signal transduction in the 
immune system. The key to the success of 
nanotechnology linked with the many aspects and 
surface modifications[126,127] is one of them, which 
can engineer these multifunctional nanoparticles to 
enhance targeted cellular uptake, and enhance the 
pharmacokinetic properties (distribution, and 
excretion) [128]. Molecular imaging 
(nanotheranostics) used [129] to determine the 
biochemical and pharmacological routes at the 
nanoscale in-vivo for most of the neuropsychiatric 
disorders [130]. 
The mind knockouts to kill the main 
Devil: Strategies for killing the stress 
In modern-day nanomedicine, there is an 
enormous need for indispensable tools in disease 
monitoring and therapy at the nanoscale, and the 
“engineered” nanomaterials have tuned to a 
harmonious set of tools as required. Thus, this 
modality has progressed to gain significant attention 
in the neurotherapeutics sciences concerning to their 
versatility of tunes characteristics [131]. Briefly, it can 
determine the advancement in the field via an 
emphasis on core properties on these engineered 
nanoplatforms. Further, modulation of surface 
modification and functionalization has assisted novel 
drug delivery of the therapeutics remedies. In 
developing these drug delivery modalities, challenges 
such as the testing of definite drug delivery, 
monitoring drug release, and inhibiting opsonization 
emerge as significant factors meant to affect the 
outcomes [132]. Therefore, it turns out to be more 
prominently essential to understand the different 
molecular mechanisms alongside the development of 
carrier vehicles. These are essential factors for how 
nanocarriers hold the drug-load, drug-bioavailability, 
and mechanism of drug targeting. Further, other 
important aspects of nanoplatforms administration- 
routes need to address as these have to face natural 
hurdles, and those are the key challenges that must be 
an emphasis on drug transportation beyond biological 
and other barriers [133]. The chief objectives of 
neuro-delivery systems must look into the key aspects 
of it, i.e. to explore the neurogenomics, diagnosis, 
discovery of potential therapeutics, and disorders of 
the nervous system. Thus, a better straightforward 
insight of nanoplatforms architecture and trials 
needed for the discovery of better drug delivery 
vehicles that address the key issues. These 
complications will be further led by the explorations 
using next-generation sequencing, genomic 
biomarkers, brain mapping, and molecular 
diagnostics to find out the efficacy of novel 
nanotherapeutics for healing neurologic disorders. 
Implementation of the Knowledge of 
nanotheranostics and nanotherapeutics will improve 
disease diagnosis, imaging of neurodegenerative 
medicine, and treatment interface while handling and 
dealing with neuropsychiatry and mental illnesses 
[134]. 




It represents stress as a sequence of incidences of 
physical, chemical, and emotional phenomena 
involving the brain. Mental tension generated this. 
Stress could be a revolving factor to generate complex 
diseases. The sequencing of these incidents produces 
a lot of biological and chemical entities that promote 
various factors to imbalance the body’s equilibrium. 
Emotional factors and originated harmful chemicals 
affect the nervous system. Overall, it is tough to 
distinguish stress and fear, and the same huddle to 
pinpoint the diseases. A three-dimensional approach 
needed here for healing the wounds of memory. On 
one side, there is a need for an exact differentiation of 
the symptoms to define the psychological imbalance, 
and the on the other side, there is a requirement of the 
evaluation requires for a proper nanotheranostics 
technique to diagnose the nanodomain, that exist in 
the stress's territory devil or where are the damaged 
neurons [32]. In the third dimension, there is a search 
for the best remedy for the ultimate attack on the main 
nanodomain by nanotherapeutics for the repair and 
regeneration of the damaged neurons. Overall, three 
dimensional therapeutic and diagnostic efforts will 
kill all causes of neurodegenerative, neuropsychiatric, 
and bipolar disorders. The aim must be to harness the 
qualities of the nanomaterials for better diagnosis, to 
explore cellular microenvironment for better 
identification of the nanodomain of the diseases, and 
this lead to finally the most and formalized efforts to 
enhance the efficiency of drug delivery to the brain for 
better regulation to the cellular microenvironment. A 
lot of variety of nanomaterials exist with unique 
abilities and capabilities which may use for molecular 
imaging, diagnosis, and treatment of 
neurodegeneration disorders. The best-identified 
nanoplatforms will be ultimately used in the 
designing of novel therapeutics to provide better 
clinical therapies. The shortcomings will further need 
to eradicate in the path towards avoidance of 
disturbance in our vision of final applicable 
nanotheranostics for neurodegenerative diseases 
[135]. Therefore, the physiology of the diseases and 
the weakness of the nanoplatforms (lipid-based, 
polymer, metal, silica, and hydrogel nanoparticles) 
must re-evaluate [136]. The up-gradation of the 
current strategies will be fruitful for a successful 
therapeutic remedy. Now, the primary emphasis 
must be on how these must co-relate to psychology, 
neuropsychiatry, nanotechnology, theranostics, and 
therapeutics to improve clinical outcomes. 
Glial cells are the key component in the brain for 
responding to the brain's response [137]. Other cell 
organelles also have their monitor forefronts for their 
contribution to the cell functioning. The biochemistry 
of the cellular details must be there with all the 
aspects, while it uses such strategies. The features of 
cell components must separately outline in every 
aspect. The understanding of complete nanodomain 
territories facilitates the designing of systems towards 
the controlling impact on the end target leading 
further to generate and govern cellular responses. 
Scale down nanofluidic tools and assemblies that 
transport fluids proficiently to the location stimulated 
or damaged cells or tissues or targeted sites have 
potential in regulating chemical and physiological 
change at the site of end affected tissue partially. More 
efficient site-specific targeting by the use of targeting 
moieties as an addition to nanodrugs has well 
studied, resulting in reduced systemic side effects and 
improve patient compliance. Closed-looped drug 
carriage nanodevices and tissue transplants 
comprising sensors on the similar chips are the 
recently advanced nanosystems that have shown 
success in obtaining the desired end impact towards 
mitigation of respective malignancy. Further, the 
nano/micro-surgical devices, nanorobots, 
nano-molecular motors, or nanobots proficient for 
navigating all over the body for healing damaged cells 
and tissues are the emerging most efficient 
nanodevices or nanosystems that can be used to 
destroy tumors or viruses and even can help in 
performing the regulated gene therapy. In 
neurotherapeutics development, the Nanorobots, in 
particular, will have unprecedented potential in drug 
delivery to brain cells aiming for precise local targets. 
Application, the Nanobots made as ‘DNA-bots’: i.e. 
nanorobots made of DNA, that release the tethered 
drug (small interfering RNA (siRNA), DNA fragment, 
and/or another chemical drug) to the environment 
when triggered by electromagnetic radiation [138]. 
Promising future medical technology that can gain, 
transmit, and save single-neuron electrical evidence 
resultant of a synaptic deal with spike frequency can 
provide with an ultimate tool called 
‘Neuronanorobots’. These nanorobots map various 
information channels in real-time in vivo in the human 
brain. Mechanically actuated DNA origami robots are 
potential thought-controlled nanobots that can alter 
the response to a brain’s cognitive state. This benefits 
the therapeutic control in disorders such as 
schizophrenia, depression, and attention deficits, 
which are among the most challenging conditions to 
diagnose and treat [139]. 
Lack of awareness into Psychiatric 
Illness: A critical review 
The symptoms of psychiatric illnesses have 
similarities with a terrible reputation of unwarranted 
behavior or cannot say it is just dangerous behavior. If 
such symptoms like hallucinations, confusion, 




suicidal thoughts, delusions, depressed mood, rapidly 
fluctuating mood, memory changes, incoherent 
thought patterns, elevated mood, addictive behaviors, 
are there then there is a need for accurate analysis of 
the symptoms and allied specific patterns of 
symptoms. Patients with psychiatric illnesses often 
have impaired insight, which means they have a 
diminished ability to understand the nature of the 
disorders. To find out a pattern of mental illnesses 
and the nature of a particular illness are two unique 
kinds of situations. Such complications make it even 
more complicated [140]. The affected person initially 
confused that he is sick or is normal. The 
interpretation is, the patients “may not understand 
the mechanisms underlying their illnesses, and this 
causes the treatment more challenging, or during 
these psychiatric illnesses, the patients rarely 
recognize that anything is wrong [141]. So a lack of 
insights, creating such troubles that define as 
anosognosia, the initial phase of severe mental illness 
which impair the capability of the concerned person 
to know and recognize someone’s illness [142]. A 
person suffering from schizophrenia may not 
understand that the voices and delusions are not real, 
or in the same case of a person having severe 
depression may not understand why others don’t 
understand him. More complicated examples are 
from the mental illness of severe dementia. In this 
disorder, patients think they can completely do 
everything. Proper functioning of the brain based on a 
complex set of brain calculations and any defects or 
failure or dysregulation of these mechanisms caused 
psychiatric illnesses [143]. It involves a pathological 
mechanism in it, and this condition interferes with 
motivational, cognitive, and emotional brain systems 
lead to dysregulation of the brain systems underlying 
insight regulation. Therefore, the affected person has 
to face a state of high internal emotion and low 
motivation. This breaks the equilibrium of normal 
functioning. To avoid anosognosia or similar 
conditions, there is a need for a proper insight 
(higher-order brain networks underlying attention, 
cognitive control, and working memory). The concept 
of cognitive is helpful, which encourages the affected 
person to improve his attention, ability, trust, a 
memory that is helpful to improve the insight [144]. 
Thus, anosognosia may cause more complications in 
psychiatric illnesses because an inaccurate insight has 
misperceptions, and this starts conflicts, and finally, 
anxiety reached the top level. In such situations, the 
patients avoid treatment or to stop taking their 
medications. Variations in awareness tactics will 
dilute the complications of anosognosia and 
accordingly patients respond to it accepting the 
persistence of mental illnesses (psychosis, depression, 
personality disorder, obsessive-compulsive disorder, 
paraphilic disorders, and substance addictions). With 
Schizophrenia, matured awareness will push not to 
accept the diseases towards the backside by exploring 
the possibilities depend on the verities of options for 
solution and which one to adopt i.e. neuroscience, 
psychiatry, psychology, social-cultural/anthro-
pological studies, linguistics and philosophy [145]. 
The etiology helped to find out the reasons for 
neuropsychiatry disorder, Schizophrenia, and to 
search the strategies for treatment linked directly with 
the processes i.e. reformulation, understanding of 
causation, and treatment method [146]. Therefore, the 
dimensions of evaluation with an outcome provide a 
platform to bring actual issues into the light, and 
many aspects of lack of insight is a line of attack. 
Insight, denial, the mental representation of the self, 
and psychiatric disorders are interrelations 
phenomenon, wherein every aspect linked with each 
other closely, and such interpretations will diagnose 
immediately, a person with psychosis. 
Conclusion and Outlook 
Because of the inflammation, undesirable 
damages start at the cellular defense system, which 
was duly opposed by initiating an immune response 
to protect from pathogenic infection, to prevent tissue 
damage, to hinder autoimmune signals within 
neurons. The fight starts with an imbalance in neuron 
cells caused by diseases. With uncontrolled 
inflammation as the prolonged one, it starts chronic 
diseases (autoimmune diseases, mental illness, 
ischemic disease, and systemic inflammatory 
response syndrome). And there are also a lot of 
diverse phenotypic consequences as dysregulation of 
immune homeostasis [147]. The efficacious diagnostic 
and efficient therapeutic agents, as (immunotherapies 
and gene therapy), can only investigate these 
conditions to target the exciting insight by the protein 
delivery. Further, it will amaze to analyze how they 
modulate the immune homeostasis to achieve 
remission of chronic inflammation. The 
immunomodulation therapies used through 
engineered autologous to the immune cells for 
correcting the disease phenotypes to achieve the 
needed outcome. These are the only scientifically 
proved remedy available. These therapeutics having 
tissue-targeting precision presented efficient 
therapeutic strategic choices base on cell 
membrane-nanotherapeutics correlation. This remedy 
looks scientifically more appropriate because the 
interactions between their surface components and 
those of the target cells can achieve the targeting 
capability. In this way of treatment, the best part of it, 
eligible for the delivery payload at the inflamed site. It 




is very well to accept that nanoformulation has 
potential in modulating inflammation. 
Nanotherapeutics induced with the cell membranes of 
cells involved in the inflammatory progression more 
efficiently used for effective targeted transport to 
inflamed tissues [148]. The innovative technology is 
"nanotheranostics, “which crosses all the hurdles, not 
properly addressed in the development of 
nanomedicines and albeit with many limitations to 
overcome [149,150]. A new variety of 
nanotheranostics of silica-coated bismuth-ferrite, are 
light-responsive caged molecular cargos, be easily 
activated with near-infrared light, and imaged at 
longer wavelengths for both detection and drug 
release processes [151]. Once light-triggered, these 
newly innovated nanotherapeutic agents release the 
drug, monitored, and quantified the release by 
recording the release inbuilt in these platforms as 
imaging-diagnosis. This method fulfills the need for 
the on-demand release of the drug, which was the 
much more awaited requirement. The other issue 
addressed during the innovation of this technology is 
that they are highly capable to save the decoupled 
imaging in tissue depth. It must use these nano smart 
devices in axonal regeneration, neurological 
operations, and molecular imaging and CNS imaging 
[152]. These nanoplatforms may cause a lit bit of 
oxidative stress, autophagy, and lysosome 
dysfunction, and signaling pathways blocking, so 
they have very low nanoneurotoxicity. 
Side effects of drugs, hundreds of metals, 
particulate, and volatile organic compounds, 
environmental pollutants, metal particles, and 
chemicals, can cause cardiovascular diseases, mental 
illnesses, brain hemorrhage, neurodegeneration, and 
dysfunction of CNS mechanisms. Ultra-fine particles 
triggered oxidative stress and neuroinflammation, 
which further affect the white matter of the neurons in 
the brain [153]. The cognitive deficits and behavioral 
impairment effect of brain-neuron connectivity. 
Finally, impairments of the parietal and temporal lobe 
functions of the brain neurons lost, by the impact of 
the mechanisms (protein aggregation, microglial 
activation, apoptosis oxidative stress injury, 
neuroinflammation, and mitochondrial dysfunction), 
triggered by neurodegeneration and as a result 
neuron disabled their routine functioning [154]. The 
therapeutic aim is to attain a significant drug 
distribution and transportation in the brain cells and 
tissues to gain desired therapeutic outcomes. 
Capabilities of the nanoplatforms i.e. minute size, 
tailored with functional modalities, and drug release 
at specific sites declared them as the best 
nanotherapeutics and nanotheranostics agents that 
can target the brain and CNS. These remedies further 
categorized into polymeric, lipids, and amphiphilic 
nanocarriers and may inject through various routes to 
prove their ability as best targeted therapy agents 
[155]. These approvals are necessary to understand 
their highly implemented mechanism and their 
successful delivery route. This kind of analysis is a 
must because the defensive barriers obstruct the 
treatment remedy timely. This is understandable and 
very useful to treat mental illnesses (depression, 
anxiety disorders, addictions, personality disorders, 
schizophrenia, eating disorders, dementia, and panic 
disorders), and meningitis. Such diseases can only be 
treated if the drug delivery is target specific to achieve 
a required therapeutic outcome. 
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